Roughly 1 percent of Americans suffer from schizophrenia, which is one of the 15 leading causes of disability worldwide, the FDA reports ... or kidney disease. Even so, the drug offers a promising ...
The US FDA has approved a new orphan drug to treat patients with Cushing’s disease who cannot be helped through surgery. Novartis’ Signifor (pasireotide diaspartate) injection has been ...
The FDA has approved Alnylam’s gene silencing drug ... As the kidney function worsens, oxalate can build up and damage other organs including the heart, bones and eyes. The disease is also ...
The FDA says people with known liver impairment or moderate to severe kidney impairment should not use the drug. Summer Colling, a senior analyst at Citeline, says the novel muscarinic mechanism ...
Even so, the arrival of Cobenfy offers a new tool for treating schizophrenia — a disease with profound ... chloride — a generic drug approved by the FDA to treat overactive bladder — as ...
17, 2024 /PRNewswire/ -- Novartis today announced that the US Food and Drug ... "The FDA approval of Kisqali for this early breast cancer population, including those with N0 disease, is a pivotal ...
SILVER SPRING, Md., Sept. 26, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of ...
a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment, drug maker Novartis announced Tuesday. "The FDA approval ...
26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ... system as a possible treatment for Alzheimer’s disease, since manipulating it seemed to reduce ...
Basel, September 17, 2024 – Novartis today announced that the US Food and Drug ... disease-free survival (iDFS) benefit was consistently observed across all patient subgroups 3-6. “The FDA ...
